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Disorders of male reproductive health,
including testicular cancer, cryptorchidism,
hypospadias, and low sperm counts, are com-
mon and may be increasing in incidence in the
Western World (Sharpe and Skakkebaek
2003; Skakkebaek et al. 2001). Although tes-
ticular germ cell cancer and low sperm counts
do not manifest until adulthood, there is
increasing evidence that these disorders, as well
as cryptorchidism and hypospadias, may have
their origins in fetal life (Sharpe 2006;
Skakkebaek et al. 2001). Based on such obser-
vations, the aforementioned disorders have
been hypothesized to comprise a testicular dys-
genesis syndrome (TDS), which stems from
dysfunction of the Leydig and/or Sertoli cells
in the fetal testis (Sharpe 2006; Sharpe and
Skakkebaek 2003; Skakkebaek et al. 2001). 
We and others have shown that fetal expo-
sure of male rats to di(n-butyl) phthalate
(DBP), or to certain other phthalates, induces
TDS-like effects (Barlow and Foster 2003;
Ema et al. 2000; Mylchreest et al. 2000), and
this may provide an animal model in which
the events in the human fetal testis that give
rise to TDS can be investigated (Fisher et al.
2003; Mahood et al. 2005). Moreover,
because human exposure to phthalates is sub-
stantial and widespread (Hauser and Calafat
2005; Koch et al. 2006; Silva et al. 2004), it is
possible that such exposures might be a cause
of TDS disorders in humans, although there is
presently only one piece of evidence to sup-
port this possibility (Swan et al. 2005). One of
the main effects of DBP and certain other
phthalates on the fetal rat testis is the suppres-
sion of testosterone production via effects on
cholesterol uptake, transport, and steroido-
genic enzyme expression (Barlow et al. 2003;
Parks et al. 2000). Therefore, one approach
toward evaluating whether phthalates can
adversely affect the fetal human testis would
be to establish whether similar suppression of
steroidogenesis, as occurs in vivo in the fetal
rat testis, can be induced in vitro in rat and
human fetal testis explants by DBP or its main
active metabolite monobutyl phthalate
(MBP). This was the primary initial aim of
the present studies. 
As well as inhibiting testosterone produc-
tion and expression of insulin-like factor-3
(Insl3) (McKinnell et al. 2005; Wilson et al.
2004) by fetal Leydig cells in the rat, in utero
exposure to DBP also induces abnormal fetal
Leydig cell aggregation (LCA)/migration
(Mahood et al. 2005). This in turn leads to
focal areas of dysgenesis within otherwise nor-
mal testes, typified by malformed tubules and
intratubular Leydig cells (Fisher et al. 2003;
Mahood et al. 2005); in adulthood, such
tubules lack germ cells (Mahood et al. 2005).
As similar aberrant morphology has been
reported in noncancerous regions of testes
from men with testicular cancer (Hoei-Hansen
et al. 2003; Sharpe 2006), which is considered
to be the severest form of TDS, we have
hypothesized that such “focal dysgenesis” may
be one of the events that leads to or reflects
altered Leydig (and perhaps Sertoli) cell func-
tion with consequent downstream effects,
namely TDS disorders (Mahood et al. 2005,
2006). In this respect, focal (abnormal) LCA
in the fetal testis can be viewed as an indicator
of dysgenesis and of potential TDS disorders,
so the demonstration that DBP/MBP could
induce LCA in vitro in cultured fetal testes
would provide an indirect way of assessing the
ability of these chemicals to induce TDS.
The aim of the present studies was there-
fore 2-fold. First, we wanted to determine
whether DBP, or its main metabolite MBP,
could induce Leydig cell effects in vitro in the
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BACKGROUND: Certain phthalates can impair Leydig cell distribution and steroidogenesis in the
fetal rat in utero, but it is unknown whether similar effects might occur in the human.
OBJECTIVES: Our aim in this study was to investigate the effects of di(n-butyl) phthalate (DBP), or its
metabolite monobutyl phthalate (MBP), on testosterone production and Leydig cell aggregation
(LCA) in fetal testis explants from the rat and human, and to compare the results with in vivo findings
for DBP-exposed rats. We also wanted to determine if DBP/MBP affects testosterone production
in vivo in the neonatal male marmoset. 
METHODS: Fetal testis explants obtained from the rat [gestation day (GD)19.5] and from the
human (15–19 weeks of gestation) were cultured for 24–48 hr with or without human chorionic
gonadotropin (hCG) or 22R-hydroxy-cholesterol (22R-OH), and with or without DBP/MBP.
Pregnant rats and neonatal male marmosets were dosed with 500 mg/kg/day DBP or MBP.
RESULTS: Exposure of rats in utero to DBP (500 mg/kg/day) for 48 hr before GD21.5 induced
major suppression of intratesticular testosterone levels and cytochrome P450 side chain cleavage
enzyme (P450scc) expression; this short-term treatment induced LCA, but was less marked than
longer term (GD13.5–20.5) DBP treatment. In vitro, MBP (10–3 M) did not affect basal or 22R-
OH-stimulated testosterone production by fetal rat testis explants but slightly attenuated hCG-stim-
ulated steroidogenesis; MBP induced minor LCA in vitro. None of these parameters were affected in
human fetal testis explants cultured with 10–3 M MBP for up to 48 hr. Because the in vivo effects of
DBP/MBP were not reproduced in vitro in the rat, the absence of MBP effects in vitro on fetal
human testes is inconclusive. In newborn (Day 2–7) marmosets, administration of a single dose of
500 mg/kg MBP significantly (p = 0.019) suppressed blood testosterone levels 5 hr later. Similar
treatment of newborn co-twin male marmosets for 14 days resulted in increased Leydig cell volume
per testis (p = 0.011), compared with co-twin controls; this is consistent with MBP-induced inhibi-
tion of steroidogenesis followed by compensatory Leydig cell hyperplasia/hypertrophy. 
CONCLUSIONS: These findings suggest that MBP/DBP suppresses steroidogenesis by fetal-type
Leydig cells in primates as in rodents, but this cannot be studied in vitro.
KEY WORDS: compensatory Leydig cell failure, di(n-butyl) phthalate, fetal testis, human, in vitro, Leydig
cell, Leydig cell aggregation, marmoset, rat, testosterone. Environ Health Perspect 115:390–396 (2007).
doi:10.1289/ehp.9490 available via http://dx.doi.org/ [Online 19 December 2006]
rat comparable to those observed in vivo;
such a demonstration would enable easier
study of the mechanisms via which such
effects occur. As a prelude to undertaking
such studies, we considered it essential to
establish if DBP treatment in vivo within the
same 48-hr time frame as used for the opti-
mized fetal rat testis cultures [gestation day
(GD)19.5–21.5] could inhibit steroidogenesis
and/or induce fetal LCA. Second, we wanted
to establish whether similar effects of
MBP/DBP were demonstrable in vitro using
human fetal testis explants. Finally, because
only limited studies with human fetal testes
in vitro are possible, we also evaluated
whether MBP treatment of the neonatal mar-
moset was able to affect Leydig cell function
during the neonatal testosterone rise.
Materials and Methods
Animals, treatments, sample collection, and
processing. Rats. Wistar rats were maintained
in our own animal facility and were fed
ad libitum with a soy-free breeding diet
(SDS, Dundee, Scotland). Adult females that
had been time-mated were treated from
GD13.5–20.5 with either corn oil vehicle
(control) or 500 mg/kg DBP (99% pure;
Sigma-Aldrich Ltd., Dorset, UK) in 1 mL/kg
corn oil administered daily by oral gavage;
this treatment regimen corresponds to the
schedule we used previously (Fisher et al.
2003; Mahood et al. 2005) and is termed
“long-term DBP treatment.” To test whether
similar effects to those induced by this treat-
ment could be induced by short-term DBP
treatment, pregnant females were treated only
on GD19.5–20.5. In both instances, animals
were then killed by inhalation of carbon diox-
ide on GD21.5, and fetuses were removed,
decapitated, and placed in ice-cold phos-
phate-buffered saline (PBS; Sigma-Aldrich).
There was a minimum of three treated
females in each group. Testes were removed
via microdissection and fixed for 1 hr in
Bouins fixative before being transferred to
70% ethanol. Testes were weighed and then
processed into paraffin wax using standard
methods and an automatic Leica processor
(Leica Microsystems, Milton Keynes, UK). 
Marmosets. Animals were captive-bred
common marmoset monkeys (Callithrix jac-
chus), maintained in a colony that has been
self-sustaining since 1973. Two studies were
undertaken. In the first, 10 newborn mar-
mosets were used, comprising five pairs of co-
twin males. Marmosets show considerable
between-animal variability that would nor-
mally necessitate the use of large numbers of
animals based on power calculations, but the
use of a co-twin study design (one twin
treated with vehicle, one twin treated with
MBP) enabled pair-wise evaluation using
smaller numbers of animals (Sharpe et al.
2002). Commencing at 4 days of age, infant
marmosets were administered vehicle or
500 mg/kg/day MBP (P1132; TCI Europe,
Zwijndrecht, Belgium). This time frame is a
critical window for testis development
(Grumbach 2005; Mann and Fraser 1996).
MBP is considered the main and active
metabolite of DBP within the body; MBP,
rather than DBP, was administered to mar-
mosets in the main studies because they have
been reported to be relatively poor metaboliz-
ers of orally administered phthalate diesters
(Rhodes et al. 1983, 1986). In the context of
the present studies, the aim was to establish
whether DBP/MBP could induce effects on
Leydig cells in the marmoset comparable to
those in the rat. For treatment, the MBP pow-
der was dissolved in dimethyl sulfoxide, then
suspended in honey. The MBP solution was
then taken up into a 1-mL syringe fitted with
soft silastic tubing at the end, and the appro-
priate dose was offered to the marmoset,
which then took it by sipping from the end of
the silastic tubing. Control co-twins were sim-
ilarly treated with vehicle only. There were no
major problems with this mode of treatment,
which we have used previously for studies
involving feeding with soy formula (Sharpe
et al. 2002). For comparison, four non–
co-twin marmosets 4–6 days of age were simi-
larly treated for 14 days with 500 mg/kg/day
DBP administered by the same method as
MBP, and data obtained was compared with
the control males from the co-twin study.
Animals were killed 4 hr after the last treat-
ment via the intraperitoneal injection of an
overdose of sodium pentobarbitone (Euthatal;
Rhone Merieux Ltd., Harlow, Essex, UK). At
death, a heparinized blood sample was
obtained by cardiac puncture; the plasma was
then separated by centrifugation and stored at
–20°C until used for the testosterone assay.
The testes were then dissected out, fixed for
6 hr in Bouins before processing as described
above for rat testicular samples. Testes were
weighed after fixation in Bouins and before
their transfer into 70% ethanol. 
In the second study, we assessed the acute
effects of MBP. Nine males 2–7 days of age
were administered a single oral dose of
500 mg/kg MBP as described above, and a
blood sample was collected 5 hr later for
measurement of testosterone levels. Controls
(n = 6) received vehicle alone. 
For the studies above, animals were treated
humanely and with regard for alleviation of
suffering. All studies were performed accord-
ing to the Animal (Scientific Procedures) Act
(1986) under Project Licence approval by the
UK Home Office. The studies in marmosets
were also approved by the local ethical com-
mittee for studies in primates.
Rat fetal testis explants. Fetal testis cul-
tures used tissue obtained from GD19.5
fetuses from untreated, time-mated females.
Recovered testes were microdissected using a
binocular dissecting microscope (Leica, MZ6)
with a transilluminated stage and external cold
lights. Each testis was microdissected into
5–7 pieces by cutting along a transverse plane
such that each testis included portions of the
coelomic epithelium and the region adjacent to
the mesonephros. Explants were cultured in
the wells of a 24-well culture plate and were
placed on a porous membrane (0.45 µm)
raised on a plastic scaffold within the culture
well. Pre-warmed (37°C) medium was added,
0.2 mL to the well and 0.2 mL within the scaf-
fold, to immerse the explants nesting on the
insert membrane. Explants were distributed
evenly between the wells per experiment with a
maximum of five per insert. Replicates of both
control and treated explants were run side by
side under identical conditions. Cultures were
incubated at 37°C for 48 hr in a humidified
atmosphere of 95% air and 5% CO2.
In a range of preliminary studies, culture
conditions were optimized based on the fol-
lowing end points: a) preservation of normal
tissue architecture without major apoptosis or
necrosis; b) maintenance of a high prolifera-
tion index (~ 30%) for Sertoli cells; and
c) maintenance of steroidogenic responsive-
ness to added stimuli. These end points were
evaluated by a) fixation of tissue explants in
Bouins and their analysis after immuno-
staining for cell-specific markers as described
previously (Mahood et al. 2005, 2006;
McKinnell et al. 2005); b) by measurement of
the incorporation of bromodeoxyuridine
(BrdU), which was added to the incubation
media for the last 4 hr of culture, and c) by
measurement of testosterone secreted into the
culture media over the 48-hr culture period.
Different culture media and additions, differ-
ent culture periods, and different age of fetal
testes were among the parameters investigated
during the optimization experiments. 
As a result of these studies, we used the fol-
lowing final protocol. We used Dulbecco’s
minimal essential medium with F12 (Gibco
2104-025; Invitrogen, Paisley, UK) to which
was added sodium pyruvate (S8636; Sigma),
bovine serum albumin (BSA; A2153; Sigma),
and an insulin–transferrin sodium–selenite
media supplement (×100; I3146; Sigma).
Explants from GD19.5 fetuses that were cul-
tured for 48 hr were used throughout. Under
the culture conditions specified, tissue architec-
ture was largely maintained and a Sertoli cell
proliferation index > 30% was demonstrable
(data not shown). Steroidogenic responsiveness
to both human chorionic gonadotropin (hCG)
and 22R-hydroxycholesterol (22R-CHO) was
also maintained. For addition to the medium,
we used the following compounds and concen-
trations: hCG (Profasi; Serono, Rockland,
MA, USA) at 0.1 IU/mL; 22R-CHO (H9384;
In vitro and in vivo effects of DBP/MBP
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Sigma) at 50 µM; ketoconazole (KTZ; K1003;
Sigma) at 100 µM; and BrdU (B9285; Sigma)
at 10 mg/mL. All of these compounds were
diluted in culture medium before addition,
with the exception of KTZ, which was pre-
dissolved at 100× target concentration in
70% ethanol (vol/vol medium). Additionally,
MBP or DBP were added to culture media at
concentrations ranging from 10–6 M to
10–3 M in 0.027% dimethyl sulfoxide.
Appropriate volumes of solvent used for the
additions were added to other cultures that
served as basal controls.
Human fetal testis explants. Human testes
were obtained after medical termination of
pregnancy at 15–20 weeks of gestation. None
of the terminations were for reasons of fetal
abnormality, and all fetuses used for the present
studies appeared morphologically normal. Fetal
testes were microdissected and placed into cul-
ture within 2–4 hr of removal from the fetus
and were maintained on ice prior to use. Ethical
permission for these studies was granted by the
Lothian Paediatrics/Reproductive Medicine
ethics subcommittee, and informed consent
was obtained from each of the female patients
involved according to national guidelines
(Polkinghorne 1989). The preparation and
culture of the human fetal testis explants used
procedures identical to those in the rat; because
the testes were larger, many more explants
were obtained per testis, and these could not
be sectioned along any particular plane as for
the rat. The stages of gestation for which
human fetal testis tissue was available broadly
corresponds to the stages used for the rat fetal
testis studies in vitro in that it encompasses the
period of maximal testosterone production by
the fetal Leydig cells as well as masculinization
of the fetus. 
Stereological analysis of marmoset testes.
Sections of testes from vehicle- and MBP-
exposed co-twins and DBP-exposed singleton
males were immunostained for 3β-hydroxy-
steroid dehydrogenase (3β-HSD) and then
subjected to stereological analysis, as described
previously (Sharpe et al. 2002; Tan et al.
2006), to determine the number of 3β-HSD–
immunopositive Leydig cells and their cyto-
plasmic volume. 
Testosterone measurement. Levels of
testosterone from blood and testes and in cul-
ture media from rat and human testis explants
were measured by radioimmunoassay, as
described previously (Mahood et al. 2005).
After dissection, testes were snap frozen on
dry ice and stored at –70°C until analysis.
Testes were defrosted and homogenized indi-
vidually in 0.5 mL PBS; a 100-µL aliquot was
then extracted with 2 mL diethyl ether,
shaken for 5 min, and placed in a bath of
methanol cooled with dry ice. The non-
aqueous portion of the extract was then
decanted, dried overnight in a fume hood,
and reconstituted in appropriate buffer for
the radioimmunoassay. Culture media were
not extracted before the assay but were
diluted as required in assay buffer. All samples
from a particular experiment were assayed
together in a single run. The limit of detec-
tion of the assay was 12 pg/mL.
Statistical analysis. Data were analyzed
using analysis of variance followed by the
Bonferroni post-test, using GraphPad Prism
(version 4; GraphPad Software Inc., San
Diego, CA, USA). Marmoset co-twin data was
analyzed using a paired t-test. Data for Leydig
cell cluster analysis and relative testosterone
production by testis explants were log trans-
formed before analysis to normalize variances.
Results
Comparison of short- and long-term exposure
to DBP in utero in the rat. We used two pri-
mary end points to compare the effectiveness
of short-term (GD19.5–21.5) and long-term
(GD13.5–21.5) in utero DBP exposure,
namely, testicular testosterone levels and the
induction of fetal LCA—both of which have
been shown previously to be key effects of
DBP on the fetal rat testis in vivo (Barlow et al.
2003; Mahood et al. 2005; Parks et al. 2000).
Our comparison showed that testicular testos-
terone levels and testicular expression of P450
side chain cleavage enzyme (P450scc) were
reduced substantially by both short- and long-
term treatment with DBP, with the shorter
term treatment regimen inducing at least as
large a reduction as the long-term treatment
(Figure 1). Similarly, both treatment regimes
induced significant LCA as judged by the shift
in proportion of small Leydig cell clusters to
medium or large Leydig cell clusters (Figure 2).
However, the shorter-term DBP treatment
regimen was noticeably less effective in induc-
ing LCA compared with the longer-term DBP
treatment regimen (Figure 2). On the basis of
these findings, we concluded that primary
Leydig cell effects of DBP treatment are
inducible in vivo within the time window
GD19.5–21.5 and that the use of explants
from GD19.5 fetuses cultured for 48 hr should
allow detection of similar effects in vitro, espe-
cially on steroidogenesis.
We also demonstrated that treatment of
pregnant rats with 500 mg/kg/day MBP from
GD13.5 to GD20.5 resulted in similar
changes to the fetal testes of male offspring at
GD21.5 (induction of LCA, induction of
Hallmark et al.
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Figure 1. Comparison of short-term (GD19.5–20.5)
and long-term (GD13.5–20.5) treatment with DBP on
(A) testicular levels of testosterone and (B) the rel-
ative expression of P450scc (55 Kd band) com-
pared with smooth muscle actin (42 Kd band), as
assessed by Western blot at GD21.5. Values shown
are mean ± SE for 3–6 testes per group. 
*p < 0.05, and **p < 0.01, compared with the respective
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Figure 2. Effect of long-term (GD13.5–20.5; A) or
short-term (GD19.5–20.5; B) treatment with DBP or
in vitro exposure of GD19.5 fetal rat testis explants
to 10–3 M MBP (C) on LCA; effects were determined
on GD21.5 (A, B) or after 48 hr culture (C). Leydig
cell cluster size was defined as follows: small clus-
ters were those that accounted for ≤ 5% of the total
Leydig cell cluster area per testis, medium clusters
accounted for 5.1–14.9%, and large clusters individ-
ually accounted for ≥ 15%. Values shown are
mean ± SE. 
*p < 0.05, and **p < 0.01, compared with the respective
controls. 
multinucleated gonocytes) as did treatment
with DBP (data not shown).
Effects of MBP or DBP on testosterone
production in vitro by rat fetal testis explants.
We found considerable variation in testos-
terone production by individual explant cul-
tures, irrespective of the culture additions, and
this necessitated the use of a reasonably high
number of repeated experiments, which were
then pooled for final analysis. In these cul-
tures, the addition of hCG always increased
testosterone production, with an average
increase above basal levels of approximately
4-fold (Figure 3). Similarly, addition of 22R-
CHO also increased testosterone production
in a consistent manner, with levels being
increased on average > 8-fold above basal lev-
els (Figure 3). In contrast, addition of KTZ,
which was added to demonstrate suppressibil-
ity of testosterone production, failed to consis-
tently induce such a decrease over a 48-hr
culture period compared with basal levels of
testosterone production (Figure 3).
Addition of DBP at concentrations
≤ 10–3 M had no effect on basal or stimulated
testosterone production (data not shown).
Addition of MBP to the culture medium at
concentrations of 10–6 M to 10–4 M (data not
shown) or 10–3 M, had no consistent or
significant effect on basal testosterone pro-
duction (Figure 3). Similarly, addition of MBP
at any of these concentrations failed to atten-
uate the increased testosterone production
induced by addition of 22R-CHO (Figure 3).
However, addition of 10–3 M MBP did
slightly, but significantly (p < 0.05), attenuate
hCG-stimulated testosterone production
(Figure 3), although there was no significant
effect observed when lower concentrations of
MBP were added to cultures stimulated with
hCG (data not shown).
Effect of MBP on LCA in rat fetal testis
explants. Addition of 10–3 M MBP slightly,
but significantly (p < 0.05), caused a shift in
Leydig cell cluster size away from small to
medium/large (Figure 2). 
Effects of DBP or MBP on testosterone
production by human fetal testis explants.
Using culture conditions identical to those
used for the rat studies above, explants of fetal
human testis were cultured in the presence or
absence of 10–3 M MBP or DBP with or with-
out the addition of hCG, 22R-CHO, or KTZ
for up to 48 hr. Testosterone production by
the human fetal testis explants over 48 hr of
culture was highly variable, irrespective of
gestational age or the culture additions.
Addition of 10–3 M MBP or DBP under basal,
hCG-, or 22R-CHO-stimulated conditions
had no significant attenuating effect on testos-
terone production, although KTZ consistently
and significantly reduced testosterone produc-
tion by approximately 80% (data not shown).
However, because histologic examination of
most of these cultured explants showed evi-
dence of central necrosis, we decided that
shorter culture periods (1, 5, and 24 hr) should
be evaluated to establish whether any effects
were demonstrable under these conditions;
results are shown for the 24 hr cultures
(Figure 4). In these samples, hCG and
22R-CHO both significantly enhanced testos-
terone secretion above basal levels, and KTZ
significantly reduced testosterone production;
however, addition of 10–3 M MBP had no
effect on testosterone secretion in the presence
of hCG or 22R-CHO or under basal condi-
tions (Figure 4).
LCA in human fetal testis explants.
Because of the dispersed distribution of Leydig
cells in human tissue compared with rat tissue,
it was not possible to perform computer-
assisted image analysis of Leydig cell clusters in
the human fetal testis explants as for the rat;
therefore, no conclusions could be drawn as to
whether MBP could induce LCA in vitro in
the human. However, visual inspection of sec-
tions of cultured testes immunostained for
3β-HSD revealed no evidence of conspicuous
LCA (not shown).
Effect of MBP or DBP in vivo on testos-
terone levels and Leydig cell volume in the
neonatal marmoset. Co-twin marmosets were
treated with either vehicle or 500 mg/kg/day
MBP for 14 days, commencing 4 days after
birth. Plasma levels of testosterone measured at
the end of the study period revealed no signifi-
cant change between control and MBP-treated
co-twins (controls, 3.3 ± 1.4 ng/mL; MBP, 3.3
± 2.1 ng/mL; mean ± SE; n = 5). Testis weight
was slightly reduced in MBP-treated co-twins
(10.8 ± 1.2 mg) compared with their co-twin
controls (11.5 ± 1.0 mg), but this difference
was inconsistent and nonsignificant. However,
it appeared from sections immunostained for
3β-HSD that Leydig cell volume per testis was
increased (Figure 5). This was confirmed by
stereological analysis, which demonstrated that
the total volume of Leydig cells (cytoplasm
plus nucleus) per testis was consistently and
significantly (p = 0.011) increased in MBP-
treated animals compared with their co-twin
controls; this change was due to an increase in
cell number in four of the MBP-treated males
and to a trebling in Leydig cell cytoplasmic
volume in the fifth MBP-treated animal
(co-twin number 2) when compared with its
co-twin control (Figure 6). Similarly, in four
marmosets treated with DBP rather than
MBP, a similar increase in Leydig cell volume
In vitro and in vivo effects of DBP/MBP
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expressed as fold change from the respective basal sample and are the mean ± SE for 3–16 replicates
from testes from four separate fetuses. 
#p < 0.001, compared with basal value. 
per testis (1.26 ± 0.17%) was evident when
compared with values for control marmosets
(0.65 ± 0.26%) from the MBP co-twin study,
although this difference did not reach statistical
significance (Student t-test). The increase in
Leydig cell volume induced by MBP/DBP was
probably attributable to increased stimulation
by raised luteinizng hormone (LH) levels
resulting from initial suppression of steroidoge-
nesis by the MBP treatment, but this could not
be confirmed directly because of the lack of
availability of an assay for marmoset LH.
Therefore, nine male marmosets 2–7 days of
age were administered a single oral dose of
500 mg/kg MBP or vehicle (controls, n = 6)
and blood was collected 5 hr later. This
showed that testosterone levels were signifi-
cantly (p = 0.019) suppressed in MBP-treated
animals (1.36 ± 0.23 ng/mL; mean ± SE) com-
pared with controls (2.75 ± 0.55 ng/mL).
Discussion
The primary objectives of the present studies
were a) to establish if Leydig cell effects of
DBP/MBP could be demonstrated in vitro
using rat fetal testis explants, and b) once such
a culture method had been established and val-
idated, to undertake comparable studies using
human fetal testis explants to establish if
DBP/MBP could exert effects in the human
comparable with those described in the rat.
However, although our studies using fetal testis
explants from GD19.5 rats showed that addi-
tion of 10–3 M MBP was able to significantly
attenuate hCG-stimulated testosterone pro-
duction, this was a relatively minor effect and
there was no effect of MBP on basal or
22R-CHO–stimulated testosterone produc-
tion by rat fetal testis explants. Similarly,
MBP induced only minor evidence of LCA
in vitro, whereas in vivo DBP treatment
beginning on GD19.5 was able to induce sig-
nificant LCA by GD21.5. There was no
attenuating effect of MBP on testosterone
production by fetal human testis explants.
Whether this reflects a genuine lack of effect
or is indicative of problems with the testis
explant approach is discussed further below.
In view of such uncertainties, we explored an
alternative approach to evaluating whether
DBP/MBP can affect steroidogenesis by fetal
Leydig cells in primates by undertaking studies
in neonatal male marmosets, the first involv-
ing MBP treatment of co-twins for a 2-week
period during the neonatal testosterone rise.
Although this study failed to demonstrate any
significant suppression of blood testosterone
levels after 2 weeks of treatment, it did provide
striking, indirect evidence that MBP exerted
negative effects on the fetal Leydig cells. This
was confirmed by a follow-up study in which
a single treatment with 500 mg/kg MBP sig-
nificantly suppressed blood testosterone levels
in neonatal marmosets. 
Addition of 10–3 M MBP significantly
attenuated hCG-stimulated, but not 22R-
CHO–stimulated, testosterone production by
rat fetal testis explants. This contrast is consis-
tent with the known mechanisms through
which DBP/MBP inhibits steroidogenesis by
fetal rat Leydig cells in vivo. Thus, DBP expo-
sure in utero reduces expression of genes encod-
ing proteins involved in cholesterol uptake and
transport into the mitochondrion, as well as
suppressing P450scc and P45017-hydroxylase
(Barlow et al. 2003; Lehmann et al. 2004).
Because this mode of action affects pathways
immediately downstream of the LH receptor, it
would perhaps be expected that MBP would be
able to attenuate hCG-stimulated testosterone
production. In contrast, because 22R-CHO
bypasses the steps in steroidogenesis that
involve transport of cholesterol into the mito-
chondrion, MBP may be unable to exert any
major inhibitory effect on steroidogenesis distal
to this step. Nevertheless, it is puzzling why
MBP caused only minor attenuation of the
hCG-induced increase in testosterone produc-
tion and why it was unable to suppress basal
testosterone production under the same cir-
cumstances, in view of the known pathways of
its effects on steroidogenesis. This suggests that
the explant culture system used in the present
studies is unable to faithfully reproduce the
main effects of DBP/MBP on steroidogenesis
that are evident in vivo. In this regard, our
findings demonstrate that short-term in vivo
treatment with DBP on GD19.5–21.5, which
matches the in vitro culture period we used,
was able to cause major suppression of
steroidogenesis in vivo in the rat. The latter
finding is consistent with earlier studies that
showed rapid effects of DBP on steroidogene-
sis in vivo by the fetal rat testis (Thompson
et al. 2004, 2005). 
The fetal human testis explant system used
in the present studies initially used conditions
identical to those used for the rat explant cul-
tures, but was then modified to include earlier
time points. Relatively modest stimulatory
effects of hCG and 22R-CHO on testosterone
production were demonstrable, whereas KTZ
caused marked suppression of testosterone
production, in contrast to its ineffectiveness in
the fetal rat testis cultures. Whether these dif-
ferences reflect genuine species differences in
control of fetal testicular testosterone produc-
tion or whether it reflects differences in the
viability/functionality of the explant cultures is
unclear. Nevertheless, under all culture condi-
tions tested for fetal human testis explants, no
significant attenuation by MBP of testosterone
production was demonstrable. In view of these
findings and the modest inhibitory effects of
MBP on testosterone production by rat testis
Hallmark et al.
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Figure 5. Representative testicular histology and
occurrence of Leydig (3β-HSD–immunopositive)
cells in the testes of neonatal marmoset co-twins
(co-twins number 5 in Figure 6) after treatment for
14 days with either vehicle (control twin, A) or
500 mg/kg/day MBP (B). Note the apparently
greater number or size of the Leydig cells in the
MBP-exposed animal. Bar = 100 µm and applies to
both images.
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Figure 6. Leydig cell parameters in neonatal mar-
moset co-twins treated for 14 days with either vehi-
cle (control twin) or 500 mg MBP/kg/day. (A) Leydig
cell volume/testis. (B) Average Leydig cell size.
(C) Total Leydig cell number per testis. The paired
t-test was used for statistical comparison. 
explants, we concluded that it is not possible
to reproduce the in vivo effects of DBP/MBP
on steroidogenesis using fetal testis explants
in vitro. It is a matter for speculation whether
this is a consequence of inadequacies of the
in vitro approach or whether it indicates that
metabolites of DBP other than MBP are the
cause of reduced testosterone production
in vivo. We therefore concluded that only
in vivo studies with DBP/MBP could be
viewed as being definitive and, as a conse-
quence, we turned to the marmoset to investi-
gate whether DBP/MBP could suppress
steroidogenesis by fetal-like Leydig cells in a
primate. 
We chose newborn male marmosets
because they exhibit a neonatal testosterone
rise comparable to human males (Grumbach
2005; Mann and Fraser 1996; McKinnell
et al. 2001) and because the Leydig cells that
make this testosterone are thought to be fetal-
type Leydig cells rather than adult-type
Leydig cells (Huhtaniemi and Toppari 1995).
Administration of MBP to co-twin mar-
mosets neonatally for 2 weeks did not sup-
press blood levels of testosterone, but there
were consistent changes in Leydig cell volume
per testis due to increased Leydig cell number
and/or size (increased cytoplasmic volume);
similar changes were observed in marmosets
treated with DBP. These findings suggest a
compensatory change caused by increased LH
stimulation of the Leydig cells (de Kretser
2004; Ochsenkuhn and de Kretser 2003), a
change that probably results from initial sup-
pression of steroidogenesis with consequent
reduced negative feedback to the hypothala-
mus–pituitary unit. Unfortunately, there is
no blood LH assay for the marmoset, so we
were unable to confirm that LH levels were
elevated. However, as an alternative, we
showed that a single treatment of neonatal
marmosets with 500 mg/kg MBP signifi-
cantly lowered testosterone levels 5 hr later, as
has been shown previously for DBP in the rat
(Thompson et al. 2004).
The finding from the co-twin study in
marmosets and comparison of the effects of
DBP/MBP on steroidogenesis by rat and
human fetal testis explants raises the impor-
tant issue of species and age differences in the
regulation of fetal/neonatal steroidogenesis. In
the fetal rat testis, testosterone production is
LH independent until at least GD19.5 of
fetal life (El-Gehani et al. 1998; Habert et al.
2001; Habert and Picon 1982). Even more
importantly, the negative feedback mecha-
nisms that would trigger increased LH secre-
tion in response to reduced testosterone
production by the fetal testis are not operative
until around this age (Habert and Picon
1982; Huhtaniemi and Toppari 1995). One
consequence of this arrangement is that sup-
pression of steroidogenesis (by DBP/MBP)
will not lead to any compensatory change
(i.e., an increase in LH secretion), at least not
until the end of gestation. 
For most of fetal life the human testis is
exposed to plentiful amounts of hCG that
might potentially override or compensate for
inhibitory effects of MBP on steroidogenesis.
After birth, it is well established that testos-
terone production in the neonatal rat, human,
and marmoset is completely LH dependent
(Grumbach 2005; Habert and Picon 1982;
Mann and Fraser 1996). As a consequence,
DBP/MBP-induced suppression of steroido-
genesis in the neonatal marmoset will lead to
reduced negative feedback and hence a com-
pensatory increase in LH secretion to restore
steroid production to normal levels. This state
of “compensated Leydig cell failure” (de
Kretser 2004) will obscure any primary
adverse effect of phthalate exposure on Leydig
cell steroidogenesis. Although we could not
demonstrate this directly in the present studies
using neonatal marmosets, our observations
are consistent with such a cascade of effects, as
elevated LH levels would be expected to
increase Leydig cell cytoplasmic volume and
or cell number per testis (Ewing and Zirkin
1983). Thus, initial inhibition of steroidogen-
esis by DBP/MBP may be compensated for so
that the original effect (i.e., lowered testos-
terone production) is no longer evident. This
should be taken into consideration when eval-
uating whether or not phthalates may induce
adverse effects on fetal steroidogenesis in the
human compared with those that are well
described in rodents.
One of the main conclusions of the present
studies is that use of fetal testis explants to
study the mechanisms of action of DBP/MBP
appears limited and is perhaps nonviable.
Though we carefully optimized explant cul-
tures for the fetal rat testis, their limited
responsiveness to MBP, when contrasted with
that observed in vivo within exactly the same
time frame, raises doubts about the utility of
the in vitro approach. Results with human fetal
testis explants raised even greater concerns,
and our finding that MBP has no inhibitory
effect on fetal Leydig cell testosterone secre-
tion in the human under such circumstances is
not one that we consider to be robust. Indeed
our studies with neonatal marmosets suggest
that MBP/DBP does have adverse effects
in vivo on Leydig cell steroidogenesis in neo-
natal primates, although the initial inhibitory
effect of DBP/MBP on steroidogenesis may be
subsequently compensated for; the ability to
“compensate” may vary between species and
between ages (fetal versus neonatal and/or
postnatal). As in vitro approaches for the study
of DBP/MBP effects on the fetal testis appear
of little value, future studies in vivo in the fetal
marmoset may offer the best direct approach
to evaluating effects relevant to the human.
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